7.22
price down icon2.30%   -0.17
after-market Dopo l'orario di chiusura: 7.12 -0.10 -1.39%
loading
Precedente Chiudi:
$7.39
Aprire:
$7.23
Volume 24 ore:
58,669
Relative Volume:
0.18
Capitalizzazione di mercato:
$5.99M
Reddito:
-
Utile/perdita netta:
$-14.93M
Rapporto P/E:
-0.0271
EPS:
-266.137
Flusso di cassa netto:
$-15.87M
1 W Prestazione:
+4.64%
1M Prestazione:
-38.97%
6M Prestazione:
-97.04%
1 anno Prestazione:
-99.30%
Intervallo 1D:
Value
$7.07
$8.18
Intervallo di 1 settimana:
Value
$6.54
$8.18
Portata 52W:
Value
$6.1478
$1,293.51

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name
Nome
Transcode Therapeutics Inc
Name
Telefono
857-301-6857
Name
Indirizzo
6 LIBERTY SQUARE, BOSTON
Name
Dipendente
7
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
RNAZ's Discussions on Twitter

Confronta RNAZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNAZ
Transcode Therapeutics Inc
7.22 5.75M 0 -14.93M -15.87M -266.14
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie

pulisher
May 29, 2025

(RNAZ) On The My Stocks Page - news.stocktradersdaily.com

May 29, 2025
pulisher
May 28, 2025

Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - citybiz

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics appoints RNA expert to advisory board - Investing.com

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics appoints RNA expert to advisory board By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan

May 28, 2025
pulisher
May 24, 2025

TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World

May 24, 2025
pulisher
May 23, 2025

Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 19, 2025

When (RNAZ) Moves Investors should Listen - news.stocktradersdaily.com

May 19, 2025
pulisher
May 16, 2025

Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail

May 16, 2025
pulisher
May 14, 2025

Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Transcode Therapeutics (RNAZ) Trading Halted Pending News Announcement | RNAZ Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World

May 14, 2025
pulisher
May 12, 2025

Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail

May 12, 2025
pulisher
May 09, 2025

(RNAZ) Investment Report - news.stocktradersdaily.com

May 09, 2025
pulisher
May 08, 2025

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan

May 08, 2025
pulisher
May 07, 2025

TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks

May 07, 2025
pulisher
May 05, 2025

TransCode Therapeutics Announces Reverse Stock Split - TipRanks

May 05, 2025
pulisher
May 05, 2025

TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan

May 05, 2025
pulisher
May 05, 2025

US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga

May 05, 2025
pulisher
May 05, 2025

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga

May 05, 2025
pulisher
May 04, 2025

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz

May 04, 2025
pulisher
May 03, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com India

May 03, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan

May 02, 2025
pulisher
May 02, 2025

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN

May 02, 2025
pulisher
May 02, 2025

For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com

May 02, 2025
pulisher
May 01, 2025

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus

May 01, 2025

Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Capitalizzazione:     |  Volume (24 ore):